FFT Wealth Management LLC Sells 62 Shares of Eli Lilly and Company (NYSE:LLY)

FFT Wealth Management LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 471 shares of the company’s stock after selling 62 shares during the quarter. FFT Wealth Management LLC’s holdings in Eli Lilly and Company were worth $363,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. AMF Tjanstepension AB raised its position in Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares in the last quarter. Values Added Financial LLC increased its stake in shares of Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after buying an additional 17 shares during the period. Cavalier Investments LLC raised its holdings in shares of Eli Lilly and Company by 211.1% in the third quarter. Cavalier Investments LLC now owns 32,556 shares of the company’s stock valued at $28,843,000 after acquiring an additional 22,090 shares in the last quarter. Peterson Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 8.5% in the third quarter. Peterson Wealth Advisors LLC now owns 716 shares of the company’s stock worth $634,000 after acquiring an additional 56 shares during the period. Finally, Kercheville Advisors LLC grew its holdings in Eli Lilly and Company by 10.3% during the 3rd quarter. Kercheville Advisors LLC now owns 8,540 shares of the company’s stock worth $7,566,000 after acquiring an additional 795 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on LLY shares. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Finally, Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $902.47 on Wednesday. The firm’s fifty day moving average is $805.87 and its two-hundred day moving average is $847.99. The firm has a market cap of $855.69 billion, a price-to-earnings ratio of 77.07, a PEG ratio of 1.40 and a beta of 0.42. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has initiated a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.66%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.